News | March 11, 2023
Bachem raises $116 million through capital increase
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Jan Aushadhi highlights achievements of women of the country at 34 locations by felicitating all women stakeholders under the scheme
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
This order is subject to initial advance payment as per the agreed terms of the contract
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.
Subscribe To Our Newsletter & Stay Updated
